Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y. Chang,Michael T. Yin,Magdalena Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho

DOI: https://doi.org/10.1101/2021.01.25.428137

2021-01-26

Abstract:The COVID-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization 1–3 , with more in the pipeline 4–7 . Furthermore, multiple vaccine constructs have shown promise 8 , including two with ~95% protective efficacy against COVID-19 9,10 . However, these interventions were directed toward the initial SARS-CoV-2 that emerged in 2019. The recent emergence of new SARS-CoV-2 variants B.1.1.7 in the UK 11 and B.1.351 in South Africa 12 is of concern because of their purported ease of transmission and extensive mutations in the spike protein. We now report that B.1.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of spike and relatively resistant to a few mAbs to the receptor-binding domain (RBD). It is not more resistant to convalescent plasma or vaccinee sera. Findings on B.1.351 are more worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely due to an E484K mutation. Moreover, B.1.351 is markedly more resistant to neutralization by convalescent plasma (9.4 fold) and vaccinee sera (10.3-12.4 fold). B.1.351 and emergent variants 13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.